BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

OTV closes $170M fundIsrael-based digital health VC OTV has changed its name from Olive Tree Ventures and closed a $170 million fund. The firm also said it hired Jose Antonio Urrutia Rivas, who was an associate...
BioCentury | Oct 13, 2020
Product Development

Gossamer takes a nosedive on Phase II results, but sees path forward in asthma

...two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2...
...two Phase II studies to treat asthma and chronic rhinosinusitis. Gossamer will not develop the PTGDR2...
...treat multiple sclerosis.TARGETSPTGDR2 (CRTH2; GPR44; DP2; CD294) - Prostaglandin D2 receptor subtype DP2 Paul Bonanos GB001 Gossamer Bio Inc. Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Dec 16, 2019
Clinical News

Novartis’ asthma failure weighs on Gossamer’s shares ahead of readout

...and LUSTER-2 trials do not support fevipiprant’s ongoing development in asthma. Fevipiprant, an antagonist of PTGDR2...
...Platelet derived growth factor receptor; PTGDR2 (CRTH2; GPR44; DP2; CD294) - Prostaglandin D2 receptor subtype DP2 Paul...
...CRTH2; GPR44; DP2; CD294) - Prostaglandin D2 receptor subtype DP2 Paul Bonanos, Associate Editor GB001 Novartis AG Gossamer Bio Inc. Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)...
BioCentury | Oct 22, 2019
Clinical News

Novartis still bullish on asthma program despite pair of Phase III misses

...FEV1) in either of the ZEAL 1 or ZEAL 2 trials. Those trials studied the PTGDR2...
...see “Biogen, Novartis Carve out Space for Their SMA Therapies” ). Another company with a PTGDR2...
...Targets: PTGDR2 (CRTH2; GPR44; DP2; CD294) - prostaglandin D2 receptor subtype DP2 Paul Bonanos, Associate Editor GB001 Novartis AG Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2) (CRTH2) (GPR44) (DP2) (CD294)...
BioCentury | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...tyrosine kinase (BCR-ABL) Chronic myelogenous leukemia (CML) Ph III Fevipiprant Prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2; CRTH2; GPR44; DP2; CD294...
BioCentury | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc (LSE:RENE) will receive...
BioCentury | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

...Price for $230 Million IPO to Sidestep Shutdown" ). Gossamer's lead candidate GB001 is a PTGDR2...
...1 α; PDGFR - Platelet derived growth factor receptor; PTGDR2 (CRTH2; GPR44; DP2; CD294) - Prostaglandin D2 (PGD2) receptor subtype DP2...
BioCentury | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

...Price for $230 Million IPO to Sidestep Shutdown" ). Gossamer's lead candidate GB001 is a PTGDR2...
...1 α; PDGFR - Platelet derived growth factor receptor; PTGDR2 (CRTH2; GPR44; DP2; CD294) - Prostaglandin D2 (PGD2) receptor subtype DP2 Paul...
Items per page:
1 - 10 of 298